Introduction
Drug delivery systems traditionally relied on passive diffusion mechanisms for targeting and releasing of therapeutically active molecules. The major problems associated with traditional delivery are poor specificity and dose-limited toxicity. Nanoparticles have found applicability in the development of novel drug delivery systems by easily overcoming toxicity problem. However, specificity of delivery has remained as a challenge. Developments in the methods of reaching to targeted tissue have lead to new and improved drug delivery platforms. Recently, active targeting has been incorporated by cell specific ligands such as antibodies, lectins, growth factor receptors. More recently, aptamers gained popularity in construction of novel actively targeted drug delivery systems . Considerable proportions of aptamer-based delivery systems have been incorporated to a variety of nanomaterials in order to improve their specific targeting properties (Chen et al., 2011; Zhou et al., 2011) .
A successful therapy starts with diagnosis and then continues with application of right dose of therapeutic molecules to the site of diseased tissues or cells. Specific detection of cancer cells is essential for early diagnosis. Cancer cell types are diverse even within the same cancer category. Fast and accurate diagnosis requires multiple specific probes which can profile more than one type of cancer cell at a given time on the same sample. In that respect, cell-based aptamer selection can supply multiple biorecognition probe molecules for any desired number of target cell type. Early diagnosis of cancer relies largely on the sensitivity of detection methods. Nanoparticle-bioconjugates has been designed to develop high sensitivity sensors. In this chapter, we will summarize the recent developments in selecting cell specific aptamer selection and development of aptamer-targeted nanoparticles for medical applications.
Selection of cell specific aptamers
Aptamers are increasingly recognized as the future affinity molecules that can readily incorporated in nanodevices for medical applications. The recent progress in cell-specific selection methodology reconfirms this premise by supplying highly specific and high affinity aptamers for any type of diseased cells. Aptamers have generally been shown to have affinities and specificity that are comparable to antibodies. They have the advantage of www.intechopen.com
The Delivery of Nanoparticles 134 high stability at a variety of extreme physical conditions such as high temperature, high salt and ionic conditions with reversible denaturation properties (Deng et al., 2001; Liss et al., 2002) . Cell-specific apramers have been obtained by following two types of Selex procedure; by using the traditional approach i) against purified protein targets or by new approaches ii) against whole cells. Using purified proteins as targets has the advantage of technical control over assessments of enrichment during Selex procedure. However, the second approach has a clear advantage when the marker target is unknown.
Aptamers selected for cell-specific proteins
Aptamers are selected through a combinatorial procedure to identify short nucleic acid sequences that recognize specific targets. The procedure is based on a repeated cycle of affinity and separation. First target molecules are brought together with a library of nucleic acids. The usual number of members in such libraries is 10 14 -10 18 random sequences. The library members will bind to target molecules if there is any recognition. The next step is the separation of bound and unbound library members through various chromatography techniques. It is commonly required to a cycle of 8 to 20 to enrich enough aptamer sequences which can be identified through sequencing since unspecific or common binder sequences will be favoured under the binding conditions. Detailed procedures on SELEX methods can be found elsewhere (Mayer, 2009) . The simplest and direct way to obtain cell-specific aptamers is to isolate a marker protein that exists on the surface of target cell type and to use that protein as a target molecule in SELEX procedure. Many cell-specific aptamers have been selected using this strategy (Janas, 2011) . The critical parameters for a successful selection are to identify cell-specific markers and to obtain the marker as pure starting material. Furthermore, the target that will be used in selection should be processed in such way that cell surface exposed regions of the molecule can be used during selection procedure. Several aptamers against cancer-related cells have been selected by using prufied proteins, including platelete-drived growth factor (PDGF) (Green et al., 1996) , vascular endothelial growth factor (VEGF) (Ruckman et al., 1998) , epidermal growth factor receptor 3 (HER3) (Chen et al., 2003) , transcription factor NFkB (Cassiday et al., 2001) , tenascin-C (Hicke et al., 2001) , prostate-specific membrane antigen (PSMA) (Lupold et al., 2002) , and ErbB in breast cancer (Kim et al., 2011) .
The aptamer against ErbB is a typical selex procedure for selecting cell specific aptamers by using purified surface proteins. Epidermal growth factor receptor family (ErbB family) of receptor tyrosine kinases plays major roles in formation and progression of human cancers. Under normal physiological, ErbB receptors play important roles in some basic cellular processes such as proliferation, differentiation, motility and apoptosis. Upon ligand binding, ErbB receptors form homo-and heterodimers leading to the activation of their tyrosine kinase domain and subsequent autocatalytic phosphorylation of specific tyrosine residues in the cytoplasmic region. Amplification and overexpression of ErbB tyrosine kinases is associated with many types of solid tumors including breast, ovarian, head and neck, gastric, bladder, colorectal, salivary, renal, prostate and lung cancers (Salomon et al., 1995) . ErbB receptors consist of an extracellular region, a single transmembrane region and a cytoplasmic tyrosine kinase domain (Cho et al., 2002) . Thus, ErbB has been a target in cancer treatment. 2'-fluorine-modified RNA aptamers for the extracellular region of the receptor has been recently selected for their recognition of breast cancer cells (Kim and Jeong, 2011) .
Aptamers selected for whole cells (cell-Selex)
Cell specific aptamers can also be selected by using whole cells as target. Instead of selecting for a purified and defined target, aptamers can be selected by subtracting the background binding sequences after a selection cycle against the target. Whole-cell approach has been increasingly adapted more commonly for selecting new aptamers. Selection using live cell target means that the cell surface proteins will be in their native conformations by the right exposure as it would be in a real application. A panel of aptamers were selected for leukemia, myeloid leukemia, liver cancer, and lung cancer by using cell-Selex procedures. The aptamers selected by cell-selex resulted in high affinity specific aptamers, but more selection rounds compared to traditional selex were required (Fang et al., 2010) . Figure 1 is a schematic representation of the cell-Selex approach. Complex targets such as tumor cells have been demonstrated to be compatible with the cell-Selex approach. The cell-selex procedure is easy to implement and faster than traditional Selex based methodologies. Most cell targets like cancer cells usually lack a clear marker protein which is highly specific for the type of application. Another important advantage of cell-selex is that the target Fig. 1 . Steps in a typical cell-Selex procedure. A single-stanraded DNA library was first incubated with target cells. Nano-binding sequences were washed away and the sequences bound on target cells were eluted and isolated. The recovered sequences were incubated with control cells (negative cells) to eliminate the sequences which bind to common epitopes present on both target and control cell surfaces. This step ensures the enrichment of target cell specific aptamers. The sequences specifically binding to target cells were then amplified to obtain the pool for the next round of selex. The enrichment of target cell binding sequences were evaluated using a binding assay and the sequences from last round were cloned and sequenced.
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Aptamers targeting tumor cells
Cancer cell types have been commonly a target for cell-Selex procedures in multiple example. An aptamer against RET receptors was selected by using cell line engineered for expressing RET tyrosine kinase receptors and background subtraction against nonexpressing cell line (Cerchia et al., 2005) . Another advantage is that cell-selex can be carried out without knowing identity of surface proteins in a target cell. Moreover, it is possible to select a panel of aptamers recognizing surface proteins which does not exist in counter selection target. Cultured T cell acute lymphoblastic leucemia (CCRF-CEM) cells was used as target and human Burkitt's lymphoma B-cells for counter-selex (Shangguan et al., 2006) . Flow cytometry has been used to monitor the enrichment of aptamers after each cycle and several high affinity aptamers (Kd in nanomolar ranges) have been obtained with specific recognition properties for CCRF-CEM cells in a mixture of cells. The same procedure was also adapted to adherent liver tumor cells by first detaching the cells with a non-enzymatic solution (Shangguan et al., 2008) . Six aptamers for Toledo and CCRF-CEM cell lines were tested for their ability to differentiate between real samples from leucemia patients . The results showed the ability of these aptamers to specifically detect molecular differences between patients.
The identity of target on the surface of cell to which an aptamer are selected using cell-selex procedures can be determined by using post-Selex procedures. TD05 is an aptamer selected against Ramos cells by using cell-Selex methodology. The aptamer was determined to bind to Ramos cell through immunoglobulin heavy mu chain which is the heavy portion of the IgM protein. B-cell receptor complex are expressed in Ramos cells and IgM is the major component of this complex. The identification of identity of aptamer target was achieved by chemically modifying the aptamers with a photoactive uracil derivative for covalent binding of aptamer with their targets. Once aptamers are bound to targets covalently, they are isolated through magnetic extraction and the target protein was determined through mass spectroscopy techniques (Mallikaratchy et al., 2007) .
Aptamers targeting stem cells
Aptamers can be used for recognition of any given cell population. The aptamer-based capture of circulating cells has been proposed for applications in regenerative medicine and tissue engineering. Mesechymal stem cells from whole bone marrow were used to generate aptamers for isolation purposes by local injection methods (Guo et al., 2006; Schaefer et al., 2007) . The aptamers recognizing osteoblasts were used to enrich them quickly and efficiently on titanium surfaces . Stents coated with capturing agents for endothelial proginator cells (EPC) from circulating blood stream have been proposed to achieve fast enthelialization of the implanted stents and hence acceleration of the healing process of vascular tissue (Aoki et al., 2005; Szmitko et al., 2006) . The capturing techniques was demonstrated with antibodies, peptides and aptamers . In one example, aptamers for high affinity for circulating porcine EPC was selected for EPC fishing (Hoffmann et al., 2008) . The application of EPC capture stents is a promising therapeutic approach to rapidly create an in vivo endothelialization of artificial surfaces. However, antibody based application has the problems due to the heterogeneity of EPC populations and the poor definition of EPC surface molecules. Therefore, the success of this approach depends on a better characterization and understanding of EPC biology and aptamers can offer the needed biorecognition molecules for the desired cell population for using in fishing approach as a successful therapy. Aptamer-based biological coatings which mimic the self healing potential of the patients' stem cell pool for vascular wall regeneration offer excitating new therapy strategies . Aptamers recognizing EPC cells have also been demonstrated as one of the cell sources useful in cardiac stem cell therapy because they can contribute to neoangiogenesis and regenerate infarcted myocardium. This new therapeutic method based on aptamers was demonstrated that the transplantation of aptamer-isolated EPCs after myocardial infarction improves angiogenesis (Sobolewska et al., 2010) .
Aptamers targeting microbial cells
Another group of cell specific aptamers has been selected for microbial cells. Aptamer-based detection of pathogens is an effective diagnostic tool in food industry and medicine. Aptamers targeting viruses, protozoa, or bacteria have been selected for biosensor development (Karkkainen et al., 2011) . A subtype of human influenza virus has been detected by aptamers demonstrating the feasibility of using aptamers in detecting pathogenic viruses in contaminated environmental and food matrixes (Gopinath et al., 2006) . African trypanosomes are a specific class of protozoan organisms responsible for the parasitic disease sleeping sickness. Aptamers specific for the African trypanosomes were reported for a surface protein located within the flagellar pocket of the parasite (Hoffmann, Paul et al., 2008) and for a surface glycoprotein of the Trypnosoma brucei subsp. Brucei (Lorger et al., 2003) . Aptamers can target against some of the surface proteins of microorganism, and the growth of the bacteria can be inhibited. The only example of therapeutic aptamer with antimicrobial properties has been demonstrated with virulent Mycobacterium tuberculosis (Chen et al., 2007) .
Drug delivering nanoparticles
Nanoparticles have many potential applications in medicine ranging from bioimaging to drug delivery. They have been synthesized from a variety of materials that could be degradable or stable, depending on the type of application. Although developing new types of materials is an exciting research area for future applications, pharmaceutical applications mostly rely on materials with history in human use to reduce the risks involved (Grama et al., 2011) . Exposing malignant tumour cells that migrate to adjacent tissues or circulate in bloodstream is critical for early detection and effective therapy. Passive delivery refers to nanoparticles loaded with drugs are administered into body without any specific targeting. The improvement over conventional methods has been obtained by adjusting the release properties of the nanoparticles by selecting special materials during the synthesis of www.intechopen.com
The Delivery of Nanoparticles 138 particles. On the other hand, increasing surface area to volume ratio for a delivery vehicle has huge benefits in improving solubility of biologically available drugs. Simple entrapment of bioactives inside nanoparticles has been shown to result in significantly higher bioavailability compared to their conventional administration methods (Mittal et al., 2007) . Designed formulations for adjusting release rate are pursued with success in multiple examples (Cozar-Bernal et al., 2011; Tsai et al., 2011) . For example, PLGA nanoparticles are biocompatible, synthesized at different grades, and safe (used for long time with humans). The release, degradation and elimination rates of PLGA nanopartiles can be tailored to desired parameters. On the other hand, nanoparticles can be functionalized for targetd delivery. Active delivery refers to incorporating a specific targeting mechanism in drugloaded nanoparticle delivery vehicle.
Aptamers have been considered as potentially interesting targeting molecules for nanoparticles. The main reason is that conjugation of aptamers to other molecules or nanoparticles is a straight-forward procedure and the attachment does not change the affinity or specificity properties of aptamers. Early diagnosis can be achieved by systems of aptamer-nanoparticle conjugates because high affinity aptamers can be obtained for tumour cells. There have been many approaches in for detection of tumor cells that is based on mechanical forces, immunohistochemistry, magnetic cell sorting, and flow cytometry. The detection based on affinity interactions is expected to yield higher efficiency and sensitivity. Antibody based affinity sensors are often found to be high levels of cross-reactivity. There are also technical challenges in crosslinking antibodies on the surface of nanodevices (Wan et al., 2010) . Thus, there is an increasing recognition for aptamers as promising utility in cancer diagnosis.
Three critical steps should be considered in designing an efficient aptamer-targeted nanoparticle drug therapy; targeting, internalization and degredation of the targeted cells by release of loaded drugs (Fig. 2) .
Aptamer-based targeting of nanoparticles
Aptamers are biorecognition molecules with multiple properties that make them attractive targeting elements. Aptamers can bind to their targets with high affinity and specificity, comparable to antibodies. The in vitro selection methodology is the major advantage ensuring availability for any desired application. Moreover, nucleic acids have unique properties that are frequently exploited in construction of nanomachines . A combination of all of the above-mentioned properties makes aptamers a desirable targeting agent for novel nanoparticle-based drug delivery systems. Recent developments in cell based Selex technology have raised expectations for medical applications required targeting of whole living cells. Two major medical applications of aptamer-based targeting of nanoparticles are bioimaging and drug delivery.
Bioimaging applications
In vivo imaging is a valuable tool in clinical diagnostics and critical to develop ultrasensitive methods (Soontornworajit et al., 2011) . Many techniques of imaging from whole organism (e.g. NMR) to specific molecular imaging (e.g. Fluorescence) are available and they are envisioned to be on the focus for developing cancer diagnosis, drug delivery, guided stem cell therapies, imaging of gene expression to monitor disease development, gene therapy, image guided surgery (Hahn et al., 2011) . Nanoparticles for bioimaging should fullfill several requirements; being dispersable and stable in vivo, low non-specific binding, and high selectivity for their targets. There are four types of nanoparticles that are commonly used in conjugation with aptamers for biological imaging applications; 1) gold nanoparticles, 2) quantum dots, 3) silica nanoparticles and 4) magnetic nanoparticles.
A nonoparticle imaging and drug delivery system has been developed by conjugating A10 aptamers to quantum dots (Bagalkot et al., 2007) . Fig. 3 shows a schematic representation of aptamer-quantum dot bioconjugate for drug delivery and imaging of delivered drugs as reported. The chemotherapeutic drug doxorubicin is an nucleic acid intercalating molecules. A bi-FRET system was prepared by attaching PSMA aptamers on the surface of quantum dot nanoparticles and doxorubicin was immobilized on the aptamer molecules by intercalation. Doxorubucin is a fluorescent molecule, but quenched by gold and nucleic acids. Therefore, the system targets the doxorubicin in non-fluorescent form to the surface of prostate cell. When the drug carrier system is internalized by the cells, doxorubicin is free from aptamer and quantum dots and become fluorescent, signalling the delivery of drug into cancer cells. Another example of quantum dot-aptamer conjugates in bioimaging was to identify and isolate subpopulations of tumor cells with high specificity. In another example, quantum dots were conjugated to liver hepatoma cell line aptamers through a sterptavidinbiotin binding. The quantum-dor-aptamer complexes were shown to specifically recognize MEAR cells specifically comapered to HeLa cells and BNL cells (Zhang et al., 2010) .
Aptamer conjugated magnetic nanoparticles are proposed for in vivo isolation of specific cells and also for magnetic resonance imaging (MRI) techniques. Aptamer-magnetic nanoparticles were used to isolate mesenchymal stem cells and endothelian progenitor cells for isolating "ready to transplant" cells as promising methods (Schaefer, Wiskirchen et al., 2007; Sobolewska, Avci-Adali et al., 2010) . Prostate cancer specific A10 aptamers conjugated to magnetic nanoparticles were used as magnetic resonance contrast agents for lower toxicity and stronger binding properties (Wang et al., 2008) .
Silica nanoparticles can be readily loaded with fluorescent molecules and highly fluorescent, stable nanoparticles can be obtained. They are stable, hydrophilic, biocompatible, chemically inert. Another advantage is that organic dyes can be encapsulated in the silica with advantages of less photobleaching. Furthermore, aptamers can be easily attached to the surface of silica. Up to 100 fold increase in sensitivity has been obtained in flow cytometry applications with dye-doped silica nanopartiles . In an effort to develop sensitive monitoring of multiple cancer cell lines, three different aptamers were conjugated to fluorescent doped silica nanoparticles . Human acute lymphoblastic leukemia cells specific aptamer, Ramos cells specific aptamer, and Toledo cells specific aptamer were used in developing multiple assays. Nanomaterials are often used for multivalent ligand binding purposes to increase the signal and sometimes enhance the binding affinity. For example, gold-silver nanorods were used as a platform for multiple aptamer immobilization. Up to 80 aptamers could be attached to rods for obtaining 26-fold higher affinity and 300-fold higher fluorescence (Huang et al., 2008) . Fig. 3 . Represantation of nanoparticle-aptamer based bi-FRET system for drug delivery and bioimaging. Doxorubicin is a fluophore and intercalates into nucleic acids. The fluorescence of doxorubicin is quenched by both gold and the aptamers. The quantum dot-aptamerdoxorubicin complex is targeted to tumor cells and internalized, and doxorubicin is released inside the cell, removing the quenching. The system targets the drug into diseased cells and the release of the drug can be monitored once it is delivered into desired site.
Aptamer-targeted drug delivery in nanoparticles
Aptamer-targeted delivery of drugs by using nanoparticles has similar advantages to bioimaging applications. The nanoparticles are specifically targeted to cell-types that are required for therapeutic molecules to act on. The drug delivery through nanoparticle encapsulation provides a vehicle for controlling the precise level and location of drugs in the body, reducing unwanted toxicity to healthy cells, lowering the doses needed. For example, drug encapsulated nanoparticles with a controlled release system can be developed and targeting to diseased cells can maximize the therapeutic efficacy and reduce undesired side effects (Langer, 2001 ).
Proof-of-concept nanoparticle-based vehicles have been developed for targeted drug delivery to prostate cancer cell surfaces with high specificity and efficiency. Once bound to tumor antigens, nanoparticles will be internalized through endocytosis. The toxic cargo of the nanoparticles will be released inside the tumour cells. Targeted delivery achieves a safe vehicle to destroy selectively the cancer cells. During the research of similar proof-ofconcept research, teh nanoparticles commonly loaded with fleorescent molecules to study the pathways, the success of targeting and release rate of cargo.
Prostate cancer as model system
Aptamers potentially can direct nanoparticles to cancer cell antigens present on the surface of tumour cells. Therapeutic nanoparticles are specifically designed to encapsulate drugs and release the drugs in preregulated and predetermined way. Prostate cancer has been the first model disease for aptamer mediated nanoparticle targeting. Prostate specific membrane antigen protein (PMSA) is a well-known marker antigen which is over expressed on tumorigenic prostatic epithelial cells. Two RNA aptamer binding to extracellular portions of PSMA has been selected and shown to adhere selectively to PMSA positive cells (Lupold, Hicke et al., 2002) . Later, an in vitro analysis device was developed in order to study the specific targeting properties of PMSA aptamer-nanoparticle conjugates (Farokhzad et al., 2005) . The device was a model of prostate cancer targeting using a microfluidic cell under physiological fluid conditions similar to microvasculature. In this experiments, the microchannels were seeded with protate cancer epithelial cells expressing PMSA or nonexpressing cells lines. Pegylated poly(lactic acid) (PLA) particles conjugated to A10 PMSA aptamer were tested for various experimental parameters mimicking the intraveneous administration of nanoparticles. The results confirmed that the particles were rapidly internalized into PMSA positive cells. The optimized aptamer-nanoparticle vehicle loaded with the chemotherapeutic drug docetaxel was later shown to reduce tumors upon injection into mice (Farokhzad et al., 2006; Cheng et al., 2007) . This example was the first targeted delivery using nanoparticle-aptamer bioconjugates. The drug delivery was achieved to be highly specific for PMSA positive cells under in vivo contions. The same system of nanoparticle-aptamer bioconjugate was shown to deliver cisplatin drug to prostate cancer cells by improving simultaneously both tolerance and efficacy in mice (Kolishetti et al., 2010) . Nanomaterials for drug delivery are required to be stable and biocompatible. Current technology can supply materials that are capable of partially fulfilling these properties. Thus, combinations of surface coatings with complementary properties are proposed for developing better functioning delivery systems. In one example, gold nanorods were encapsulated within thin and uniform layer of silica shell for enhanced stability and and a layer of PEG was used for biocompatibility. The composite nanoparticles were functionalized with PSMA aptamers and tested for their ability to target the nanopartciles to prostate cancer cells (Hu et al., 2011) .
Other examples
Vasculature targeted delivery is an attractive strategy due to the phenotypic changes on the endothelial cell surface associated with pathological conditions such as inflammation and angiogenesis. E-selectin is expressed in inflammed vaculator in advanced tumors and it can be used as marker for pathological vasculator. A high affinity thio-backbone modified aptamers against E-selectin were recently selected by using recombinant-expressed protein (Mann et al., 2010) . E-selection aptamers were incorporated in liposomes, the targeting efficiency and pharmokinetic properties of delivery were investigated (Mann et al., 2011) . CCRF-CEM recognizing aptamers (sgc8c) were conjugated to doxorubucin-doped silica nanoparticles and delivered leukemia cells with high specificity and efficiency (He et al., 2011) .
Aptamer-based gating systems
The efficacy of drug therapy is determined by two parameters; efficient targeting of drug to the diseased site and the controlled release of the drug. The potential of aptamer-based targeting have been demonstrated in multiple examples as presented in above sections in order to improve specific delivery properties of drug carrying nanoparticles. The bioactive molecules in the nanoparticles were released with traditional mechanism such as internalization, endocytosis and degradation of nanomaterial once the nanoparticles attach to the surface of diseased cell surface. However, aptamers can be also exploited in controlling the release of drugs from nanoparticles. Two recent reports indicate to future potential of aptamers as targeting and gating agents in nanoparticle-based drug delivery. A snap-top type molecular gate using aptamer-gold nanoparticle complex to control the release of cargo of silica nanoparticles was shown to respond to aptamer target for stimuliresponsive release . In another report, switchable control of the gating in nanocarriers through aptamers was shown to control the release rate of active molecules in response to taptamer target stimuli .
Conclusion
Nanoparticle-aptamer bioconjugates provide exciting prospects in medical nanotechnology for future disease treatments. The advancements in nanomaterial field together with cellSelex procedures offer the controlled release polymer systems conjugated to aptamers tweaked to the any target diseased cell. Therefore, it is possible to produce a diverse range of specific and selective nanoparticle-aptamer bioconjugates. Drug delivery vehicles can improve the therapy of a myriad of important human diseases by using aptamernanoparticle bioconjugates. Aptamer-based targeting has already achieved progress in demonstrating the usability nanoparticle-aptamer bioconjugate systems to improve nanomaterial drug delivery vehicles in model animals. Next critical step for realization of potentials of bioconjugated nanoparticles will be clinical realization studies in near future. It is worth to indicate that with aptamers being in principle available for any kind of target (e.g., small metabolites, proteins, lipids, ions), it can be anticipated a straightforward transfer of proof-of-concept results to other applications when developing efficient drugdelivery systems. Finally, aptamer-based molecular gating of nanoparticle cargo can bring new approaches in drug delivery field by combining targeting and controlled release in the same mechanism.
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